Education
About Us
Working with TipRanks
Follow Us
Akari Therapeutics (AKTX)
NASDAQ:AKTX
AKTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.85 - $4.40
Previous CloseN/A
Volume16.29K
Average Volume (3M)30.67K
Market Cap
$15.42M
Enterprise Value$21.25M
Total Cash (Recent Filing)$5.97M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta<0.01
Next Earnings
Apr 08, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding24,758,558
10 Day Avg. Volume44,538
30 Day Avg. Volume30,666
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-6.40
P/FCF Ratio0.00
Enterprise Value/Market Cap1.38
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.06
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Akari Therapeutics News
PremiumCompany Announcements
Akari Therapeutics Appoints New CEO Abizer Gaslightwala
PremiumCompany Announcements
Akari Therapeutics Showcases Advancements in Cancer Treatment
PremiumCompany Announcements
Akari Therapeutics Announces New CEO and Director Changes
PremiumCompany Announcements
Akari Therapeutics Appoints Torsten Hombeck as CFO---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AKTX FAQ
What was Akari Therapeutics’s price range in the past 12 months?
Akari Therapeutics lowest stock price was $0.85 and its highest was $4.40 in the past 12 months.
What is Akari Therapeutics’s market cap?
Akari Therapeutics’s market cap is $15.42M.
When is Akari Therapeutics’s upcoming earnings report date?
Akari Therapeutics’s upcoming earnings report date is Apr 08, 2025 which is in 8 days.
How were Akari Therapeutics’s earnings last quarter?
Akari Therapeutics released its earnings results on Aug 19, 2024. The company reported $0 earnings per share for the quarter, the consensus estimate of N/A by $0.
Is Akari Therapeutics overvalued?
According to Wall Street analysts Akari Therapeutics’s price is currently Overvalued.
Does Akari Therapeutics pay dividends?
Akari Therapeutics does not currently pay dividends.
What is Akari Therapeutics’s EPS estimate?
Akari Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Akari Therapeutics have?
Akari Therapeutics has 24,758,558 shares outstanding.
What happened to Akari Therapeutics’s price movement after its last earnings report?
Akari Therapeutics reported an EPS of $0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went down -0.278%.
Which hedge fund is a major shareholder of Akari Therapeutics?
Currently, no hedge funds are holding shares in AKTX
---
Company Description
Akari Therapeutics
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
---
AKTX Stock 12 Month Forecast
Average Price Target
―Technical Analysis
TG Therapeutics
―
InflaRx
―
Annovis Bio
―
Kalaris Therapeutics
―
Inhibrx Biosciences Inc
―
---